Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.

2025-521455-23-00 Protocol CLI-06467AC1-02 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 11 Sep 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol CLI-06467AC1-02

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 68
Countries 1
Sites 2

Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

Key facts

Sponsor
Chiesi Farmaceutici S.p.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trial duration
11 Sep 2025 → ongoing
Decision date (initial)
2025-08-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

VersionLevelCodeTermSystem organ class
25.0 PT 10086943 Hypoxic ischaemic encephalopathy neonatal 100000004868

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Chiesi Farmaceutici S.p.A.

Sponsor organisation
Chiesi Farmaceutici S.p.A.
Address
Via Palermo 26/a
City
Parma
Postcode
43122
Country
Italy

Scientific contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVEOPMENT

Public contact point

Organisation
Chiesi Farmaceutici S.p.A.
Contact name
GLOBAL CLINICAL DEVEOPMENT

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruiting 68 2
Rest of world 0

Investigational sites

Bulgaria

2 sites · Ongoing, recruiting
Medical Center Comac Medical Ltd.
N/A, Ulitsa Urvich 13, Krasno Selo District, Sofia
Medical Center Comac Medical Ltd.
N/A, Ulitsa Sveti Georgi Sofiyski 3, 1606, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-09-11 2025-09-15

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-05-15 Bulgaria Acceptable
2025-08-05
2025-08-05
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-17 Bulgaria Acceptable
2025-08-05
2025-10-17
3 SUBSTANTIAL MODIFICATION SM-1 2025-11-21 Bulgaria Acceptable
2026-01-06
2026-01-07
4 SUBSTANTIAL MODIFICATION SM-2 2026-01-16 Bulgaria Acceptable 2026-02-27